Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Nanobiotix    NANO   FR0011341205

NANOBIOTIX (NANO)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 07/13 05:36:21 pm
17.08 EUR   +5.11%
07/12NANOBIOTIX : Financial | NANOBIOTIX revenue for the 1st quarter of 2..
PU
07/12NANOBIOTIX : 2nd quarter earnings
CO
07/09NANOBIOTIX SA : half-yearly sales release
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
15(c) 16.01(c) 15.81(c) 16.25(c) 17.08(c) Last
204 233 543 307 274 143 239 226 452 936 Volume
+2.88% +6.73% -1.25% +2.78% +5.11% Change
More quotes
Financials (EUR)
Sales 2018 8,33 M
EBIT 2018 -25,4 M
Net income 2018 -22,2 M
Finance 2018 12,7 M
Yield 2018 -
Sales 2019 12,9 M
EBIT 2019 -28,5 M
Net income 2019 -27,8 M
Finance 2019 4,23 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 35,7x
EV / Sales2019 23,8x
Capitalization 310 M
More Financials
Company
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer.The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells.It also engages in the development of magnetic particles and laser activated... 
More about the company
Surperformance© ratings of Nanobiotix
Trading Rating : Investor Rating :
More Ratings
Latest news on NANOBIOTIX
07/12NANOBIOTIX : Financial | NANOBIOTIX revenue for the 1st quarter of 2018
PU
07/12NANOBIOTIX : 2nd quarter earnings
CO
07/09NANOBIOTIX SA : half-yearly sales release
07/05PHARMAENGINE : Announces Positive Topline Results from Global Pivotal Trial of P..
AQ
06/28PHARMAENGINE : Announces Positive Topline Results from Global Pivotal Trial of P..
AQ
06/23NANOBIOTIX : Announces Positive Phase II/III Topline Data In Soft Tissue Sarcoma..
AQ
06/21NANOBIOTIX : announces positive phase II/III topline data in soft tissue sarcoma..
AQ
06/06NANOBIOTIX' Management statement on recent share price variation
GL
06/06NANOBIOTIX : Financial | NANOBIOTIX’ Management statement on recent share ..
PU
05/15NANOBIOTIX : 1st quarter earnings
CO
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/13Nanobiotix $NANO Revenue for the 2nd Quarter of 2018 | Business Wire
1
06/28This may not be in the top 3, but it has definitely triggered the most intere..
1
06/28Here's something new -- I asked to look over Nanobiotix's statement on sarco..
3
06/22By administering intratumoral injections of the nanoparticles prior to extern..
4
06/22Nanobiotix Achieves Primary and Secondary Endpoints in Ph II/III Study in Sof.. 
More tweets
Qtime:34
News from SeekingAlpha
2015NANOMETRICS : Well-Positioned In A Promising Industry 
2015Nanometrics' (NANO) CEO Timothy Stultz on Q4 2014 Results - Earnings Call Tra.. 
2015Nanometrics Incorporated (NANO) Q4 2014 Results - Earnings Call Webcast 
2015Nanometrics beats by $0.03, beats on revenue 
2015Notable earnings after Monday?s close 
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | 4-Traders
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 30,0 €
Spread / Average Target 85%
EPS Revisions
Managers
NameTitle
Laurent Lévy Chief Executive Officer
Laurent Condomine Chairman-Supervisory Board
Alain Dostie Chief Operating Officer
Philippe Mauberna Chief Financial Officer
Elsa Borghi Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
NANOBIOTIX15.17%363
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147